A retrospective real-world study is drawing attention to psychotic complications seen during use of subcutaneous foslevodopa/foscarbidopa infusions in Parkinson’s disease. Researchers examined 198 patients and focused on episodes involving hallucinations, delusions and related disturbances. The dataset is observational and retrospective, but its clinical value is in capturing adverse-event patterns under routine conditions outside tightly controlled trials. The findings help inform prescriber monitoring and patient counseling for infusion-based levodopa delivery formats that aim to smooth motor fluctuations. As such delivery technologies move deeper into clinical practice, identifying and characterizing the risk profile—including the frequency, timing, and potential patient factors associated with psychiatric events—becomes part of the pathway to broader adoption. For clinicians, the practical implication is tighter vigilance for psychotic symptoms after initiation and during dose adjustments, especially in patients with known vulnerability to hallucinations or those receiving other neuropsychiatric-active therapies.